by ASTCT Talks and Oncology on the Go
This ASTCT and CancerNetwork® collaboration recaps key hematologic oncology advances from the 2026 ASCO Annual Meeting, featuring expert discussion from a live X Spaces session. Highlights...
by Alex Kadhim
Researchers from the University of Lausanne and University Hospital of Zurich in Switzerland demonstrate that PD‑1–targeted CAR‑T cells can selectively reduce HIV reservoir cells and delay...
by Alex Kadhim
Researchers from leading institutions in Shanghai, China, identified a key immune signature driving steroid‑refractory acute graft‑versus‑host disease (SR‑aGvHD), involving expanded CD28+ CD8+...
by ASTCT Talks and Oncology On the Go
In a special ASTCT Talks and Oncology on the Go collaboration, experts discuss a case study examining how CAR T-cell therapy may contribute to rare gastrointestinal T-cell lymphomas. The...
by Alex Kadhim
Researchers from the Hackensack University Medical Center have demonstrated that EZH2, a chromatin-modifying epigenetic enzyme, promotes alloreactive T cell survival during graft-versus-host...
by Alex Kadhim
In a single-center phase 2 study (CAR-PRISM; NCT05767359), researchers from the Dana Farber Cancer Institute have shown that a single infusion of BCMA-directed CAR T cell therapy with...